[
    {
        "category": "company",
        "datetime": 1743525776,
        "headline": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?",
        "id": 133655250,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual\u2019s DNA to treat [\u2026]",
        "url": "https://finnhub.io/api/news?id=5cf4ff087101d537a7e41182bdb48e03b64c09cab86a7889737050ee576dc1f3"
    },
    {
        "category": "company",
        "datetime": 1743522637,
        "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
        "id": 133645467,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration\u2019s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is \u201cnot good for the biotech industry even beyond vaccines.\u201d Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a \u201csignificant negative\u201d for the biopharma and biotech sectors. \u201cNOT GOOD\u201d FOR BIOTECH SECTOR: RBC Capit",
        "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    },
    {
        "category": "company",
        "datetime": 1743519300,
        "headline": "VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates",
        "id": 133655251,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.",
        "url": "https://finnhub.io/api/news?id=567f789ed0c55726d6edac0d9a9db9ba0f45a81a73c27ad28d89b38cd8d7aa2e"
    },
    {
        "category": "company",
        "datetime": 1743507025,
        "headline": "These biotech names aren't facing 'huge concern' from tariffs",
        "id": 133645380,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime\u00a0here.",
        "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce"
    },
    {
        "category": "company",
        "datetime": 1743438960,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
        "id": 133638616,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=97e07341275215b42d21d8a30a8dc6c5860d121b27c213079eb3b800688f8435"
    },
    {
        "category": "company",
        "datetime": 1743430200,
        "headline": "Intellia Focuses on Pipeline Development Amid Stiff Competition",
        "id": 133627901,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.",
        "url": "https://finnhub.io/api/news?id=8195ef88c62076e0d29f7e1998b1800e0b7f49a7f07c30bf70afca5baf173fc1"
    },
    {
        "category": "company",
        "datetime": 1743428032,
        "headline": "Jim Cramer on Vertex Pharmaceuticals (VRTX): \u201cRevolutionary Pain Drug on the Horizon!\u201d",
        "id": 133627902,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer looked at recently. Jim Cramer, the host of Mad Money, offered an optimistic perspective on the market on [\u2026]",
        "url": "https://finnhub.io/api/news?id=d95f8d09f5c9e7782b3eb79c89d9ce8dbfd7d263069bb4ce4c38b86bb33c1052"
    },
    {
        "category": "company",
        "datetime": 1743420937,
        "headline": "Vertex halts development of diabetes cell therapy after trial failure",
        "id": 133625700,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.",
        "url": "https://finnhub.io/api/news?id=9245b0e3c5b44be3cd08cc75f33f1adb04ec21571f8e7b66e5f7b5558e92f540"
    },
    {
        "category": "company",
        "datetime": 1743419700,
        "headline": "PGIM Jennison Global Opportunities Fund Q4 2024 Commentary",
        "id": 133626837,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206067205/image_2206067205.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The PGIM Jennison Global Opportunities Fund returned -0.6%, holding up slightly better than the MSCI ACWI Index. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=4e3ccc7be59fb7d5a1ce2d2968438f82e1cc05399ebdc5fbccad36a50cfe99f3"
    },
    {
        "category": "company",
        "datetime": 1743416586,
        "headline": "Vertex Pharmaceuticals Incorporated : 2024 (2024 Political Engagement Principles)",
        "id": 133626501,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "POLITICAL ENGAGEMENT PRINCIPLES Our Mission Every day, Vertexians work hard to improve the lives of patients. In so doing, we recognize the importance of...",
        "url": "https://finnhub.io/api/news?id=09fd4a7ea73a953e870eecd0105ed1077cb09a2adf7a43eafdeae0d9b24ab4a6"
    },
    {
        "category": "company",
        "datetime": 1743403200,
        "headline": "PGIM Jennison Focused Growth Fund Q4 2024 Commentary",
        "id": 133624801,
        "image": "",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=737ff5ee66dd78153317776bacd4fec7f6e999436982756dea21c4a22bae1c46"
    },
    {
        "category": "company",
        "datetime": 1743317400,
        "headline": "abrdn U.S. Small Cap Equity Fund Q4 2024 Commentary",
        "id": 133604282,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/625756386/image_625756386.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The abrdn U.S. Small Cap Equity Fund gained (gross of fees) and outperformed the Russell 2000 Index for Q4 2024. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=3f0d637f5e10d5b1bbffce496906099a771a504797461989f691005ecbb8fb92"
    },
    {
        "category": "company",
        "datetime": 1743306600,
        "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
        "id": 133594341,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205513/image_1322205513.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b"
    },
    {
        "category": "company",
        "datetime": 1743303600,
        "headline": "Putnam Small Cap Growth Fund Q4 2024 Commentary",
        "id": 133591728,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1256967959/image_1256967959.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Small-capitalization stocks posted positive returns for the quarter, but they lagged their large-cap counterparts.",
        "url": "https://finnhub.io/api/news?id=086f90c366c0865a539b216018d547603a65c2c0af2513b02f966627528ccf5a"
    },
    {
        "category": "company",
        "datetime": 1743303000,
        "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
        "id": 133590926,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    },
    {
        "category": "company",
        "datetime": 1743268474,
        "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price",
        "id": 133558229,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company announced the completion of enrollment for the VX-264 and Zimislecel studies, though only Zimislecel remains on track for potential regulatory submissions following more promising outcomes. This progress, along with the recent approval of ALYFTREK in the UK for cystic fibrosis, might have...",
        "url": "https://finnhub.io/api/news?id=0586ca99e3756547dda8740be498345fc8666ca91da5dd999f50498e2f40a981"
    },
    {
        "category": "company",
        "datetime": 1743203219,
        "headline": "Is Vertex Pharmaceuticals (VRTX) The Most Expensive Stock Insiders Are Dumping In March?",
        "id": 133527617,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market [\u2026]",
        "url": "https://finnhub.io/api/news?id=9badcf5c34672d2b56494ae78649d55e1a8ce282bd20979735db7b2028bbcf06"
    },
    {
        "category": "company",
        "datetime": 1743198610,
        "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know",
        "id": 133527618,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior day's close.",
        "url": "https://finnhub.io/api/news?id=7af7b2a34767f471f366974794765be6dbed16685dcd5cf932d6bc5129de8695"
    },
    {
        "category": "company",
        "datetime": 1743192300,
        "headline": "Vertex Announces Program Updates for Type 1 Diabetes Portfolio",
        "id": 133527619,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "BOSTON, March 28, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company\u2019s type 1 diabetes (T1D) portfolio.",
        "url": "https://finnhub.io/api/news?id=c06c7862cd3a0c2dc617359905daa3280a547c2fae2d5395681dd5d471e4ccd4"
    },
    {
        "category": "company",
        "datetime": 1743181507,
        "headline": "Vertex to Cease Clinical Trials on Diabetes Treatment",
        "id": 133524919,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "By Katherine Hamilton Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement. There were...",
        "url": "https://finnhub.io/api/news?id=cf5a1722c09f6ba92e0d70751ee4b530eb475b595809cc01c821d5bcbda0c4c8"
    },
    {
        "category": "company",
        "datetime": 1743179820,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
        "id": 133638618,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=4bfdcae8d90a2ec98cb6fc2f2a83725379271d65abc34a0de02a92bf6725ddd4"
    },
    {
        "category": "company",
        "datetime": 1743178319,
        "headline": "Vertex Pharmaceuticals Inc - Expects $400 Million Impairment Charge For VX-264 - SEC Filing",
        "id": 133524671,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "Vertex Pharmaceuticals Inc: * VERTEX PHARMACEUTICALS INC - EXPECTS $400 MILLIONIMPAIRMENTCHARGE FOR VX-264 - SEC FILINGSource text:Further company coverage: ...",
        "url": "https://finnhub.io/api/news?id=f4f76b952b7a494462e45c9a26281d8f9f0a6489a642de0f7154daad5c0003a9"
    },
    {
        "category": "company",
        "datetime": 1743157800,
        "headline": "Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession",
        "id": 133507752,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a recession.  If you're wondering which stocks might do well even if the U.S. economy slumps, you may want to look back to see which ones thrived during the last prolonged recession -- the Great Recession, which took place between December 2007 and June 2009.  The S&P 500 fell by 36% during that period.",
        "url": "https://finnhub.io/api/news?id=bf04ebd697f9cdeb2e0e69ac7a019179d226177ea3e9cfdec17e74a71d17357e"
    },
    {
        "category": "company",
        "datetime": 1743123300,
        "headline": "ClearBridge Growth ESG Portfolios Q4 2024 Commentary",
        "id": 133504563,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054522581/image_2054522581.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "A market broadening in the fourth quarter sparked by Donald Trump\u00e2\u0080\u0099s election victory and a further interest rate cut from the US Federal Reserve proved momentum-driven and short-lived.",
        "url": "https://finnhub.io/api/news?id=6b0ea926305a2a4ba933c3161d88aa79688369656de128124c20e105b3f2a570"
    },
    {
        "category": "company",
        "datetime": 1743116100,
        "headline": "ClearBridge All Cap Growth Portfolios Q4 2024 Commentary",
        "id": 133504109,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182036952/image_2182036952.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Despite inklings of a market broadening sparked by Donald Trump\u00e2\u0080\u0099s election victory and further interest rate cuts from the Fed, the post-election rally proved short-lived.",
        "url": "https://finnhub.io/api/news?id=832a9b4407a105064fc1cfb530dbd13f63fb60b6b2405433153447afc3b9240f"
    },
    {
        "category": "company",
        "datetime": 1743115200,
        "headline": "Putnam U.S. Small Cap Growth Equity Q4 2024 Commentary",
        "id": 133504075,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283342758/image_1283342758.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "In a challenging quarter for small cap stocks, the portfolio underperformed its benchmark, the Russell 2000 Growth Index, based on gross and net returns.",
        "url": "https://finnhub.io/api/news?id=bb37aae6926f0931df4589b3d4affaef88834634fc199f697f881b661ea04de7"
    },
    {
        "category": "company",
        "datetime": 1743112816,
        "headline": "Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors",
        "id": 133505725,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.",
        "url": "https://finnhub.io/api/news?id=17f8cfcc751b0337dde4e37c185a645ae3b0e1f499d019ffb8e10563bf38e7b7"
    },
    {
        "category": "company",
        "datetime": 1743085320,
        "headline": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
        "id": 133481428,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.",
        "url": "https://finnhub.io/api/news?id=f58df00bb20b8c43e492a2a40109df7467ae78a0e89aab182a4cab400cb2a554"
    },
    {
        "category": "company",
        "datetime": 1743060600,
        "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
        "id": 133467152,
        "image": "",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    },
    {
        "category": "company",
        "datetime": 1742994009,
        "headline": "Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock",
        "id": 133457274,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.",
        "url": "https://finnhub.io/api/news?id=8c8b3e070b588157a815f0d70586ceecc8a97e19423b2546b9fa4a7811d3f987"
    },
    {
        "category": "company",
        "datetime": 1742986560,
        "headline": "Google Takes on Microsoft and OpenAI. The Search Giant Is Fighting to Keep Its Top Spot.",
        "id": 134149235,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Google Takes on Microsoft and OpenAI. The Search Giant Is Fighting to Keep Its Top Spot.",
        "url": "https://finnhub.io/api/news?id=57820037aa192f3c45a5eaf910be03f638b8e8421ddaeabbcd1366bfb8fd08a2"
    },
    {
        "category": "company",
        "datetime": 1742984229,
        "headline": "The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs",
        "id": 133456250,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward investment. Read more on RNA stock update.",
        "url": "https://finnhub.io/api/news?id=e9c604309b041827af4cb535b2f3a76212b25575ce814704f2600525c158cd74"
    },
    {
        "category": "company",
        "datetime": 1742975700,
        "headline": "Microsoft Takes On Alphabet With This AI Advance. It\u2019s Copilot vs Gemini.",
        "id": 133448357,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Microsoft Takes On Alphabet With This AI Advance. It\u2019s Copilot vs Gemini.",
        "url": "https://finnhub.io/api/news?id=06d8bd8ee5d72e5ad6342c05489cd93d7056518034b6461ea928a6b0d7eba8e5"
    },
    {
        "category": "company",
        "datetime": 1742834160,
        "headline": "Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market",
        "id": 133363996,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=98e0c06c7c493e89f954906e39f3403616b83ff8ddfc8af2475dff14a4f4c052"
    },
    {
        "category": "company",
        "datetime": 1742740812,
        "headline": "Jim Cramer on Vertex (VRTX): \u201cA Revolutionary Anti-Pain Drug\u201d",
        "id": 133337960,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]",
        "url": "https://finnhub.io/api/news?id=6d33fcde6a62d1378464dfb9d5f209501167c201bb1e57feccb98977ed05b697"
    },
    {
        "category": "company",
        "datetime": 1742673840,
        "headline": "2 Beaten-Down Stocks to Buy on the Dip",
        "id": 133325401,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical therapies.  CRISPR Therapeutics' shares are down by 41% over the trailing-12-month period, while Merck's have declined by 22%.  It's not hard to figure out why CRISPR Therapeutics, a gene-editing specialist, isn't performing well.",
        "url": "https://finnhub.io/api/news?id=3a49b5cda79451bb0ee3ddf0fd71e0bafa7b8f0d2ef400c5c5a912bfd53fa6d7"
    },
    {
        "category": "company",
        "datetime": 1742613600,
        "headline": "BUZZ Investing: Fed's Glimmer Of Hope Amid Market Corrections",
        "id": 133312894,
        "image": "",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=03408afa1952080181545aeb839354c59d0d91de887cdbdfbdbaa304f5c44835"
    },
    {
        "category": "company",
        "datetime": 1742593817,
        "headline": "Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know",
        "id": 133325402,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=8e021c65b4e8bf886a26af8b242fe136d4a6e0a594c00527f9d47a40eeb0ccab"
    },
    {
        "category": "company",
        "datetime": 1742571030,
        "headline": "Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?",
        "id": 133325403,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=ed4adf1c967609e5ba39af6f29bb7fed7e628006b69bcb11c0e485364e0fbc15"
    },
    {
        "category": "company",
        "datetime": 1742558455,
        "headline": "As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point",
        "id": 133325404,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.",
        "url": "https://finnhub.io/api/news?id=6575f75d09ace1343fbdfcb1a6a0217962aca9abe25ff2ac18ffaa302b368d0f"
    },
    {
        "category": "company",
        "datetime": 1742461970,
        "headline": "Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
        "id": 133325405,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Let\u2019s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.",
        "url": "https://finnhub.io/api/news?id=661997f746daf698d0000c7f7328d3e6c49fc655d722e02e6e14965810a8bc71"
    },
    {
        "category": "company",
        "datetime": 1742461500,
        "headline": "Invesco Health Care Fund Q4 2024 Commentary",
        "id": 133273550,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
        "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    },
    {
        "category": "company",
        "datetime": 1742421619,
        "headline": "Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should Know",
        "id": 133325406,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading day.",
        "url": "https://finnhub.io/api/news?id=98fc121f7d0d3e8895f897200a6d6053149643d7984795f24169779a5ab01ad7"
    },
    {
        "category": "company",
        "datetime": 1742393815,
        "headline": "Is Vertex Pharmaceuticals (VRTX) the Best Diabetes Stock to Buy According to Billionaires?",
        "id": 133325407,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best diabetes stocks to buy according to billionaires. The Growing Market and Innovation in Continuous Glucose Monitoring (CGM) Technology The WHO [\u2026]",
        "url": "https://finnhub.io/api/news?id=b35d3c84f2e8c3d0419630e441c5aca4c762ff3a90aa0ff875ea5b870b28a091"
    },
    {
        "category": "company",
        "datetime": 1742392920,
        "headline": "Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next",
        "id": 133325408,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.  Whatever happens, though, some stocks are still worth investing in and holding on to through market volatility.  Two excellent examples are DexCom (NASDAQ: DXCM) and Vertex Pharmaceuticals (NASDAQ: VRTX).",
        "url": "https://finnhub.io/api/news?id=989dc23fd50976f7c93b8d3b4525c25cd138e8d1acc996e1b49d20a19402920c"
    },
    {
        "category": "company",
        "datetime": 1742391707,
        "headline": "CRISPR Therapeutics AG (CRSP): A Bull Case Theory",
        "id": 133325409,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this article, we will summarize the bulls\u2019 thesis on CRSP. CRISPR Therapeutics AG (CRSP)\u2019s share was trading at $40.97 as of March 18th. CRSP\u2019s trailing and forward P/E were 22.55 and 23.36 respectively according to Yahoo Finance. CRISPR Therapeutics [\u2026]",
        "url": "https://finnhub.io/api/news?id=a2f75f1f2e1f2cef3c70d20196a416aefdc9da1068f35e28efc5d88fc75dbc15"
    },
    {
        "category": "company",
        "datetime": 1742375111,
        "headline": "A Look Back at Therapeutics Stocks\u2019 Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack",
        "id": 133325410,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Let\u2019s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.",
        "url": "https://finnhub.io/api/news?id=58de3c880479f92f19e7e06b68c21f7daecfb386106851c9e25231da44197327"
    },
    {
        "category": "company",
        "datetime": 1742289975,
        "headline": "Vertex Pharmaceuticals (VRTX): One of the Best Biotech Stocks to Buy According to Billionaires",
        "id": 133325411,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best biotech stocks. Although biotech stocks had a \u201cchallenging\u201d year in 2024, JPMorgan believes that some of the industry\u2019s companies [\u2026]",
        "url": "https://finnhub.io/api/news?id=57b899312a6ce244d89ae5fe28dbb216f4950e4b3321377cbe507e39eec8ee89"
    },
    {
        "category": "company",
        "datetime": 1742281082,
        "headline": "Is Vertex Pharmaceuticals (VRTX) Among the Best High Growth Stocks?",
        "id": 133325412,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of 13 High Growth Large Cap Stocks To Invest In. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best high growth stocks to invest in. After two years of 25%+ gains, some investors worry that stocks are overvalued. Historically, [\u2026]",
        "url": "https://finnhub.io/api/news?id=7720c39f422b8ae2147c6511cf7db2d364a2964d7eef5c8e121076d674a4bb9c"
    },
    {
        "category": "company",
        "datetime": 1742229360,
        "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
        "id": 133220140,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=e2c7bdfc8c7b648610eb1bda97a7488e0dab7bf81e09fb479352aca1b1ce897f"
    },
    {
        "category": "company",
        "datetime": 1742222820,
        "headline": "Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?",
        "id": 133325413,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.",
        "url": "https://finnhub.io/api/news?id=bf9125a928b2541c92959de7eb7e6841737e2d1b2738cb443d7bcf6605981c82"
    },
    {
        "category": "company",
        "datetime": 1742208420,
        "headline": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
        "id": 133268520,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility.  David Jagielski (Eli Lilly): A top pharma stock that I wouldn't hesitate to buy right now and hold for years is Eli Lilly.  There is no shortage of reasons to be bullish on the stock, as it looks poised to eventually become the first healthcare company to top a $1 trillion valuation.",
        "url": "https://finnhub.io/api/news?id=efeebbda87a3df47cb4cb72c9de4a39d5c804552a9e86c12bcd28c2300385170"
    },
    {
        "category": "company",
        "datetime": 1741966234,
        "headline": "Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?",
        "id": 133185492,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=8a9472d76f342b45e76743994bd8e566a24bbc72fda771b03a210ce6f8279ce4"
    },
    {
        "category": "company",
        "datetime": 1741945860,
        "headline": "3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
        "id": 133184482,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Many investors view the healthcare sector as a safe haven when the stock market is turbulent.  Here are three no-brainer healthcare stocks to buy with $1,000 right now.  AbbVie's product lineup is led by blockbuster drugs targeting autoimmune diseases, with Rinvoq and Skyrizi delivering especially strong sales growth.",
        "url": "https://finnhub.io/api/news?id=1fcb64ba72c5293d17db314666aaa3d41ddd60f3991245113ebc4f76295dfc8e"
    },
    {
        "category": "company",
        "datetime": 1741902616,
        "headline": "Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today",
        "id": 133185494,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.",
        "url": "https://finnhub.io/api/news?id=ee95621a3c1b1409300a23b4216248bc7eee413b32cd4714c4e007873e41b9b5"
    },
    {
        "category": "company",
        "datetime": 1741898461,
        "headline": "CRISPR Therapeutics: An Uninspiring Start For Casgevy",
        "id": 133165247,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/113456532/image_113456532.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious \"Hold\" within a barbell portfolio.",
        "url": "https://finnhub.io/api/news?id=774ffbfb9ba9f0ea1819e4599c214d421107e388e57de809a7ebbbf22c59949c"
    },
    {
        "category": "company",
        "datetime": 1741880408,
        "headline": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
        "id": 133185354,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=525462baf97cedb30694019df10579d06c99d166a081e7f12a22589e2e566f2e"
    },
    {
        "category": "company",
        "datetime": 1741816819,
        "headline": "Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know",
        "id": 133185496,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.",
        "url": "https://finnhub.io/api/news?id=14d607e151e25a29a82f823be5046455ee9fe774c0cdf93fe13f786ff60d7d6e"
    },
    {
        "category": "company",
        "datetime": 1741804171,
        "headline": "Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds",
        "id": 133185497,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in [\u2026]",
        "url": "https://finnhub.io/api/news?id=4ef96eb4da1962efe1167a26ed59efc02c814b69418999e924e1168bd84595da"
    },
    {
        "category": "company",
        "datetime": 1741793414,
        "headline": "Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?",
        "id": 133185498,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=f297b0f96ecf5627c1bb5d0f1adf3831195761050b8de52bda165ebfa870c982"
    },
    {
        "category": "company",
        "datetime": 1741784276,
        "headline": "Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?",
        "id": 133185499,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Parnassus Investments, an investment management company, released the \u201cParnassus Core Equity Fund\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, U.S. stocks rose, closing up a robust 2024. The Fund (Investor Shares) surged 0.28% (net of fees) in the quarter underperforming the S&P 500 Index\u2019s [\u2026]",
        "url": "https://finnhub.io/api/news?id=45a637544b4f90f35ce141fb273d70eca4a00e8b5a79077c6761d3ad50d5a2c5"
    },
    {
        "category": "company",
        "datetime": 1741728555,
        "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
        "id": 133140400,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164745052/image_2164745052.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
        "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f"
    },
    {
        "category": "company",
        "datetime": 1741700400,
        "headline": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "id": 133136678,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    },
    {
        "category": "company",
        "datetime": 1741699320,
        "headline": "Company News for Mar 11, 2025",
        "id": 133185500,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Companies in The News Are: VRTX, TSLA, NVDA, COIN",
        "url": "https://finnhub.io/api/news?id=9227bc8febe3e99f1595de6d14c9204f10d98efa745c9337848ee11f897e2817"
    },
    {
        "category": "company",
        "datetime": 1741685460,
        "headline": "Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever",
        "id": 133185501,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The Nasdaq Composite Index (NASDAQINDEX: ^IXIC) is now squarely in correction territory.  Here are my picks for the two smartest stocks to buy during the current Nasdaq correction and hold forever.  Amazon (NASDAQ: AMZN) stock has been hit especially hard in the latest market sell-off.",
        "url": "https://finnhub.io/api/news?id=ec907998fe65639b19d62a8f05744d4959c5ddd08e3b2c50ca4912ea9dba717c"
    },
    {
        "category": "company",
        "datetime": 1741683917,
        "headline": "3 Reasons to Avoid VRTX and 1 Stock to Buy Instead",
        "id": 133185502,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.",
        "url": "https://finnhub.io/api/news?id=33cacc8ce5bd83ad95e7b40b577eb791a31eb3c9180bad391f6d48fa30a9bec9"
    },
    {
        "category": "company",
        "datetime": 1741681500,
        "headline": "Where Will Vertex Pharmaceuticals Be in 10 Years?",
        "id": 133185503,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).  The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.  The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.",
        "url": "https://finnhub.io/api/news?id=a2899b769ddda01dedafc02b4b0c80d657d9417c35b63ebf8685e2e3115b5f07"
    },
    {
        "category": "company",
        "datetime": 1741618823,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)",
        "id": 133123349,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ETCompany ParticipantsCharlie Wagner -...",
        "url": "https://finnhub.io/api/news?id=e1a10b3dd8df397c29fe62547e72b4959b34021d5d221b89c18330899e231406"
    },
    {
        "category": "company",
        "datetime": 1741609800,
        "headline": "If I Could Buy Only 1 Growth Stock, This Would Be It",
        "id": 133185504,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "There are hundreds of publicly traded companies on various equity markets worldwide.  Investors choose to put their hard-earned money into specific companies based on their preferences, risk tolerance, goals, investment horizons, available capital, etc. Because these factors vary quite a bit from one person to the next, choosing a single stock everyone \"should\" invest in is hard.  Read on to discover why many could benefit from investing in this terrific company.",
        "url": "https://finnhub.io/api/news?id=870aef70ee2152c0b3cf6575858853f2f797029d0624cefba242a628c9391f81"
    },
    {
        "category": "company",
        "datetime": 1741448460,
        "headline": "3 Magnificent Growth Stocks to Buy in March",
        "id": 133185017,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry.  With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.",
        "url": "https://finnhub.io/api/news?id=b9e2ea71c875b99b34fdb720c216a37bf14fa2904bbfc4b0be137be181e6570e"
    },
    {
        "category": "company",
        "datetime": 1741368084,
        "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment",
        "id": 133185506,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK\u00ae, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market presence. This announcement, alongside FDA approval in December 2024, likely bolstered the company's recent stock performance. Over the last quarter, Vertex's share price increased by 5.11%, despite broader market challenges, including economic slowdown concerns and significant...",
        "url": "https://finnhub.io/api/news?id=2fc3a7185c0a06dc522f00a8f8c0574fd2384f39cc4a0c5d774bf4567d7db20a"
    },
    {
        "category": "company",
        "datetime": 1741366445,
        "headline": "Update: Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary",
        "id": 133185507,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "(Updates with response from Optum Rx in the third and fourth paragraphs.) Vertex Pharmaceuticals",
        "url": "https://finnhub.io/api/news?id=f7d26d5921ea51db6bab7ddf6b0145d4cae7e9052350a1779efc76b8c22ed480"
    },
    {
        "category": "company",
        "datetime": 1741359720,
        "headline": "Vertex Announces UK MHRA Approval of ALYFTREK\u00ae (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
        "id": 133185508,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "LONDON, March 07, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK\u00ae (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutati",
        "url": "https://finnhub.io/api/news?id=1251a4cafcf44197e53e4c931b5d097ffee17b4c065c31c589954a067031a8f7"
    },
    {
        "category": "company",
        "datetime": 1741340400,
        "headline": "ClearBridge All Cap Growth Strategy Q4 2024 Commentary",
        "id": 133090333,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413858192/image_1413858192.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=81b2942b352a432f4c8934f624e12169c63abda471c2d5a524050f1bd70c8ce0"
    },
    {
        "category": "company",
        "datetime": 1741287079,
        "headline": "Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary",
        "id": 133184346,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) said Thursday that its Journavx non-opioid pain killer has been added",
        "url": "https://finnhub.io/api/news?id=febb3e0205db7bdb8408a3ff5cec111a46e346ddb7ceae73322083c7d9a70ec5"
    },
    {
        "category": "company",
        "datetime": 1741278960,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
        "id": 133094327,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=d3d96e63321b67888a98b43cc5d7194a171702ef2a1d52d44191c4c4255b8313"
    },
    {
        "category": "company",
        "datetime": 1741251600,
        "headline": "Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating",
        "id": 133052238,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152048919/image_2152048919.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why VRTX stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=16db238cae25ea7f997745cc7c59ffaab45a89d8383c10f86732f849e26be5dd"
    },
    {
        "category": "company",
        "datetime": 1741192620,
        "headline": "Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",
        "id": 133055515,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=ced06cf422c39a5aa39b4a2d62146085ab4ee9214236998f6034036c680c5351"
    },
    {
        "category": "company",
        "datetime": 1741172877,
        "headline": "Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value",
        "id": 133185510,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value amid broader market declines. In this environment, a good stock is often characterized by strong fundamentals and the potential for growth despite external pressures, making it an attractive consideration for those looking to navigate current market challenges.",
        "url": "https://finnhub.io/api/news?id=b94c2f525ef9e81f1edeab6865cce78281104156ea7c98f62c96bfe9bed26f6a"
    },
    {
        "category": "company",
        "datetime": 1741086900,
        "headline": "5 Top Stocks to Buy in March",
        "id": 133185511,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "2025 has gotten off to a choppy start as some of the most valuable U.S.-based companies are dragging down the major stock market indexes.  Here's why four Motley Fool contributors think chip giants Nvidia (NASDAQ: NVDA) and Micron Technologies (NASDAQ: MU), travel services company Airbnb (NASDAQ: ABNB), biotech behemoth Vertex Pharmaceuticals (NASDAQ: VRTX), and high-yield dividend stock Enterprise Products Partners (NYSE: EPD) are worth buying in March.  Daniel Foelber (Nvidia): Despite blow-out results and upbeat guidance, Nvidia's stock price fell 8.5% last Thursday after reporting fourth-quarter and full-year fiscal 2025 results.",
        "url": "https://finnhub.io/api/news?id=b0a1dfea44b026364e34ef5ed3bbe36e82b298f86928de5ae7a33fe7c7b67b1d"
    },
    {
        "category": "company",
        "datetime": 1741027316,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)",
        "id": 132969860,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ETCompany ParticipantsDavid...",
        "url": "https://finnhub.io/api/news?id=2da4b0e961bf231d4ce46b8f1287e6f84b2ca3ab9fabffad17686a5f97890b21"
    },
    {
        "category": "company",
        "datetime": 1740997440,
        "headline": "Alger Small Cap Growth Fund Q4 2024 Commentary",
        "id": 132954190,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1185664943/image_1185664943.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Class A shares of the Alger Small Cap Growth Fund underperformed the Russell 2000 Growth Index during the fourth quarter of 2024. Read more here.",
        "url": "https://finnhub.io/api/news?id=43063af5dc60779f35873d0c807f29ff74878ba5741af25d14b70b52b3254539"
    },
    {
        "category": "company",
        "datetime": 1740760620,
        "headline": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
        "id": 132959208,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=07d51560d7269ee3434ba9510d761ade6411c7ca67ef1a087299a16642e0fe1c"
    },
    {
        "category": "company",
        "datetime": 1740727383,
        "headline": "Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO\u00ae in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations",
        "id": 132904704,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time-...",
        "url": "https://finnhub.io/api/news?id=b3dfe9d61d541ddd6b099abd92d94da4eb81d1292465d791f49f41d5611082a7"
    },
    {
        "category": "company",
        "datetime": 1740726000,
        "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "id": 132907806,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8"
    },
    {
        "category": "company",
        "datetime": 1740433380,
        "headline": "Hartford Healthcare Fund Q4 2024 Commentary",
        "id": 132867176,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/200386256/image_200386256.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Hartford Healthcare Fund (I share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=92dd3485faf0f8a524606aed0034df8cfd23fdf8f703e993912a4e84ebe7bca2"
    },
    {
        "category": "company",
        "datetime": 1740089880,
        "headline": "Madison Sustainable Equity Fund Q4 2024 Investment Strategy Letter",
        "id": 132824708,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307631/image_1367307631.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The S&P 500 ended 2024 with a 25% gain for the year. This marks the second consecutive year of gains exceeding 25% and the third such occurrence in the past four years.",
        "url": "https://finnhub.io/api/news?id=03de51df45863f6ef7a5d23f5e7b4c62c20e182f856ac8ddd40b344488931e86"
    },
    {
        "category": "company",
        "datetime": 1739895064,
        "headline": "Vertex to Participate in Upcoming March Investor Conferences",
        "id": 132779755,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "Vertex Pharmaceuticals Incorporated today announced management participation in three upcoming investor conferences.Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David...",
        "url": "https://finnhub.io/api/news?id=c094acd6f5d978763f17420537f1b06bbc419cb286fb74a7e159471e3a42deb8"
    },
    {
        "category": "company",
        "datetime": 1739778900,
        "headline": "Parnassus Growth Equity Fund Q4 And 2024 Annual Investment Commentary",
        "id": 132748104,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2071111658/image_2071111658.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index\u00e2\u0080\u0099s 7.07%. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=0e91fa81ce79a6a058f2186406389749201e7c0b0c8e23f98408dde776ffd009"
    },
    {
        "category": "company",
        "datetime": 1739770500,
        "headline": "Parnassus Core Equity Fund Q4 And Annual 2024 Investment Commentary",
        "id": 132744221,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482218589/image_1482218589.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Parnassus Core Equity Fund returned 0.28% (net of fees) for the quarter, underperforming the S&P 500 Index\u00e2\u0080\u0099s 2.41%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=a4aff68571cfd19f93df65ce183c68ea191d09d1690c4e73b2cf4f1edb4cf3b9"
    },
    {
        "category": "company",
        "datetime": 1739480280,
        "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary",
        "id": 132709614,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172483014/image_172483014.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.",
        "url": "https://finnhub.io/api/news?id=8d306981723ae6baaa27a41df72a2ad77528d2ff9fae45eee20d34b6483d2dcd"
    },
    {
        "category": "company",
        "datetime": 1739398529,
        "headline": "Tracking Tweedy Browne Portfolio - Q4 2024 Update",
        "id": 132699017,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Tweedy Browne\u00e2\u0080\u0099s 13F portfolio value decreased from $2.10B to $1.48B. Click here to read more about the trades and holdings of the portfolio.",
        "url": "https://finnhub.io/api/news?id=36841fc1a25c10cbffaaa7adcc03b8e81975493129d249f1926d024e62faea3a"
    },
    {
        "category": "company",
        "datetime": 1739392800,
        "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
        "id": 132698753,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    },
    {
        "category": "company",
        "datetime": 1739291820,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
        "id": 132684137,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=7391708fef2b3b9f7304e5df4a8f97003029a3d9b162d7691ffa6572aa7aea08"
    },
    {
        "category": "company",
        "datetime": 1739265649,
        "headline": "Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.",
        "id": 132661877,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.",
        "url": "https://finnhub.io/api/news?id=83b346e6af8faad84f404a91f2ee01b6ecafc097f5c63ccf4794eb1ab11e5094"
    },
    {
        "category": "company",
        "datetime": 1739219170,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript",
        "id": 132653059,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ETCompany ParticipantsSusie Lisa - Senior Vice...",
        "url": "https://finnhub.io/api/news?id=1660a10c42a72fae589dd62259a4db56441211bd0f0aaf4540e5b650ae700204"
    },
    {
        "category": "company",
        "datetime": 1739212954,
        "headline": "Vertex Pharmaceuticals Incorporated 2024 Q4 - Results - Earnings Call Presentation",
        "id": 132646422,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2024 Q4 earnings call.",
        "url": "https://finnhub.io/api/news?id=ba4094da11af65f9b5db2337521d0c710b732d86c9c7ef135d541c514f1fc24b"
    },
    {
        "category": "company",
        "datetime": 1739206560,
        "headline": "Vertex Pharmaceuticals Posts Higher 4Q Revenue",
        "id": 132661897,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Posts Higher 4Q Revenue",
        "url": "https://finnhub.io/api/news?id=4d2e21d70084f44d67851a8d927b483f9678fce501f9ddc0b9539712db3b0776"
    },
    {
        "category": "company",
        "datetime": 1739186400,
        "headline": "Tweedy, Browne Fund Q2 2024 Commentary",
        "id": 132634530,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191113686/image_2191113686.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The bull market in global equities continued to modestly grind ahead in the 2nd quarter. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=18ab4999a3d94c838a04ef9829ae164a8f996e52efd547c6a976ee06f69b8f41"
    },
    {
        "category": "company",
        "datetime": 1739149200,
        "headline": "Tweedy, Browne Fund Q4 2024 Commentary",
        "id": 132630159,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358927461/image_1358927461.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Setting aside a rather brief hiccup mid-quarter, the bull market in global equities continued in force during Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=e02945fdabaed045becd514285a918f53131f289764f0daac05ac0a6e35faaf7"
    },
    {
        "category": "company",
        "datetime": 1739117700,
        "headline": "2 Biotech Stocks to Buy Hand Over Fist in February",
        "id": 132631695,
        "image": "https://g.foolcdn.com/editorial/images/806426/physician-shaking-patients-hand.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA).  Vertex Pharmaceuticals is starting the year strong.  On Jan. 30, the company announced that the U.S. Food and Drug Administration had approved Journavx, the first non-opioid oral pain signal inhibitor to earn the green light from regulators.",
        "url": "https://finnhub.io/api/news?id=b97ddc3df1b2caf60c5b46e55e6a1686939d6e8a0d78676536cea0ce70bc7c83"
    },
    {
        "category": "company",
        "datetime": 1739106254,
        "headline": "Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For",
        "id": 132631696,
        "image": "https://s.yimg.com/ny/api/res/1.2/BsVjiKvWfXwFYurrH4Fong--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here\u2019s what to look for.",
        "url": "https://finnhub.io/api/news?id=8e916cc1a71888f22c26b69e5d72a51e22269991083fa9319d302cfe57fa8e63"
    },
    {
        "category": "company",
        "datetime": 1739095200,
        "headline": "What To Expect in the Markets This Week",
        "id": 132631426,
        "image": "https://www.investopedia.com/thmb/l4rbuT2RhPHMm6xQFGFoMtD0rzw=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/INV_CokeErnsRecap_2Q23_GettyImages-1484916701-b5e5d2e73ae944c48a329ccdd789b0e8.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Coming up: January CPI inflation, retail sales, Jerome Powell congressional testimony, earnings from Coca-Cola, McDonald\u2019s, Cisco, and Shopify",
        "url": "https://finnhub.io/api/news?id=f8d268a9f10aef303ead2daf589949ead173d84f418e54795421fe7aca858ab8"
    },
    {
        "category": "company",
        "datetime": 1739082525,
        "headline": "Wall Street Week Ahead",
        "id": 132626374,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165462299/image_2165462299.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Stay informed on upcoming economic data releases and earnings reports with Wall Street Breakfast, now available as a daily podcast on Seeking Alpha, iTunes,...",
        "url": "https://finnhub.io/api/news?id=071849bcbb73239bb7f241dcbbddc19f39b46050c2c90626c9f5f1da36484d98"
    },
    {
        "category": "company",
        "datetime": 1739012400,
        "headline": "Consumer Companies In Focus Next Week As McDonald's, Coca-Cola, Unilever Report Earnings",
        "id": 132603561,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "This week's earnings releases include consumer companies. A number of IPOs are set to begin trading and Jan. CPI data will be released on Wednesday. See more.",
        "url": "https://finnhub.io/api/news?id=525fb5c6227a36042e04ceb1fde2894a5f63eb685316ff76ecaa664ae5f1af29"
    },
    {
        "category": "company",
        "datetime": 1738951170,
        "headline": "Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement",
        "id": 132600240,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192903839/image_2192903839.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks. Click to find out why FULC is a Hold.",
        "url": "https://finnhub.io/api/news?id=abef70b46b659a4128f83cb3af188df4aade2854a033bfa14b123df143c13b8d"
    },
    {
        "category": "company",
        "datetime": 1738837380,
        "headline": "The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex",
        "id": 132574521,
        "image": "https://media.zenfs.com/en/zacks.com/7bc8bbeae2e0a87a69be234f543981cd",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=cb95312edd76c5faf66c5601aa2759c8e1e7ec0737a83f2134614bb8f0df28ca"
    },
    {
        "category": "company",
        "datetime": 1738770506,
        "headline": "Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)",
        "id": 132567872,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316503044/image_1316503044.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising partnerships. Click for my CRSP stock update.",
        "url": "https://finnhub.io/api/news?id=8e4ead3b5ec7fa74154cd7fbe8b49b72ff4aad1233f823d51fcf67060a99d474"
    },
    {
        "category": "company",
        "datetime": 1738767240,
        "headline": "Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?",
        "id": 132631699,
        "image": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).",
        "url": "https://finnhub.io/api/news?id=fac579c60cb7ded21ab0ae16cb97520ceb561c707953989f4e5df4b57b6f9846"
    },
    {
        "category": "company",
        "datetime": 1738764925,
        "headline": "Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics",
        "id": 132631700,
        "image": "https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.",
        "url": "https://finnhub.io/api/news?id=1eb0dbb284e570915301b52faf7e95e72851d69894eab8f1e4fceff9ecbea91f"
    },
    {
        "category": "company",
        "datetime": 1738743300,
        "headline": "ClearBridge Growth Portfolios Q4 2024 Commentary",
        "id": 132562056,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1061700868/image_1061700868.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Performance was supported in the quarter by AI-indexed semiconductor and software provider Broadcom, along with a cohort of disruptors. Read more here.",
        "url": "https://finnhub.io/api/news?id=c9fafe55af9968c5fff0f9de4be882738f07d01c01f0ff6eb7bb997d3221ceb4"
    },
    {
        "category": "company",
        "datetime": 1738681239,
        "headline": "Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release",
        "id": 132631701,
        "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "url": "https://finnhub.io/api/news?id=e1b79362b9f3fe3b8702c0fca20a6f7cacec33bfd9aae5fa912b09fb802deced"
    },
    {
        "category": "company",
        "datetime": 1738671000,
        "headline": "Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?",
        "id": 132631702,
        "image": "https://g.foolcdn.com/editorial/images/806256/gettyimages-1253877215.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings.  The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or surgery.  Today, with this new Vertex option available, is this biotech player a no-brainer buy?",
        "url": "https://finnhub.io/api/news?id=fc5fb277d30a75837730e24a369dd8cd57b9f233abc7f6558b3072217d445b6f"
    },
    {
        "category": "company",
        "datetime": 1738663340,
        "headline": "US Stocks Estimated To Be Trading Below Intrinsic Value In February 2025",
        "id": 132631703,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "As of February 2025, U.S. stock markets have been experiencing heightened volatility due to recent tariff announcements and ongoing concerns about trade policies, which have impacted major indices like the S&P 500 and Nasdaq Composite. Amidst this uncertainty, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value, offering potential opportunities for those seeking to navigate the current market landscape effectively.",
        "url": "https://finnhub.io/api/news?id=af77b97e88911ce9c94dac0176bed0fe2b4e343da064cf7d9f407ba9d4a8696b"
    },
    {
        "category": "company",
        "datetime": 1738623022,
        "headline": "Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note",
        "id": 132631704,
        "image": "https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.",
        "url": "https://finnhub.io/api/news?id=3324e58708ccc43371d3277d015d648e51a4bceea7a53b69869c581f88cda157"
    },
    {
        "category": "company",
        "datetime": 1738600620,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "id": 132547326,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=be5a585290e3c9d107b524e67ef9c990baa74b46264e4875020f6471898d3282"
    },
    {
        "category": "company",
        "datetime": 1738593000,
        "headline": "3 Magnificent Stocks to Buy and Hold Forever",
        "id": 132631705,
        "image": "https://g.foolcdn.com/editorial/images/805884/young-woman-smiling-hands-behind-head.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Here's why they view Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) as magnificent stocks to buy and hold forever.  David Jagielski (Eli Lilly): A forever stock you can put in your portfolio and not worry about is Eli Lilly.  The healthcare company's robust financials, solid pipeline of drugs, and growing dividend highlight three of the best reasons to invest in the business.",
        "url": "https://finnhub.io/api/news?id=fd72e612ada35bc5670c8297faeb2e426fa2803f17b74d0d6562e1cd7d6c5647"
    },
    {
        "category": "company",
        "datetime": 1738591380,
        "headline": "Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?",
        "id": 132631706,
        "image": "https://media.zenfs.com/en/zacks.com/4e067dcfead6ca72f3d024ca0e8efd5c",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
        "url": "https://finnhub.io/api/news?id=b490aaf08d5e8c33354217a14152cd84cf028aa11c522842d371ab8326a0a9ee"
    },
    {
        "category": "company",
        "datetime": 1738591212,
        "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
        "id": 132631707,
        "image": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
        "url": "https://finnhub.io/api/news?id=891dd6ded1235f135c4972a30541459064d15d41f3564526823ee0cc04f70aae"
    },
    {
        "category": "company",
        "datetime": 1738586580,
        "headline": "Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?",
        "id": 132574537,
        "image": "https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.",
        "url": "https://finnhub.io/api/news?id=3756ee24b5eb170011c6a956f2e8f2d6a862afbbd59715cfc25bc7247edf4f36"
    },
    {
        "category": "company",
        "datetime": 1738501560,
        "headline": "Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?",
        "id": 132631709,
        "image": "https://g.foolcdn.com/editorial/images/806025/fda-approved.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days.  On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).  Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain.",
        "url": "https://finnhub.io/api/news?id=815641c24dd1f3505e60b221e94dff3957cb708a4591341e3b7fd7a2cb2db6b3"
    },
    {
        "category": "company",
        "datetime": 1738492500,
        "headline": "Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?",
        "id": 132631710,
        "image": "https://g.foolcdn.com/editorial/images/806019/individual-investor-looking-at-stock-charts-getty.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street.  Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news.  The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025.",
        "url": "https://finnhub.io/api/news?id=6d3f7b9aac55b69331499d8b947de9f53884fe2ca19282a08965ae294bc92f1d"
    },
    {
        "category": "company",
        "datetime": 1738448271,
        "headline": "Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain",
        "id": 132512854,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171631791/image_171631791.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and why it is a Buy.",
        "url": "https://finnhub.io/api/news?id=9edeb1828d8f97fda559e4147f2b55e99e0d22649494f45d438b2e6bca901cee"
    },
    {
        "category": "company",
        "datetime": 1738418721,
        "headline": "Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank",
        "id": 132631711,
        "image": "https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Scotiabank raised the firm\u2019s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex\u2019s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm\u2019s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx\u2019s value proposition as an opioid alternative, however, should not b",
        "url": "https://finnhub.io/api/news?id=a6e624bd87e5c577763a8094dd2a3ea171159387c6096e34a70e5188eb25b6d7"
    },
    {
        "category": "company",
        "datetime": 1738396800,
        "headline": "Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine",
        "id": 132510138,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186971023/image_2186971023.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.",
        "url": "https://finnhub.io/api/news?id=cbbf2320ee5c9baf20089e6ab46b37affc06a54f1a3ee03d7d693d3897db75be"
    },
    {
        "category": "company",
        "datetime": 1738358220,
        "headline": "These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More",
        "id": 132631712,
        "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts\u2019 estimates, and Chevron posts adjusted earnings below expectations.",
        "url": "https://finnhub.io/api/news?id=8ec491052b15ab4e30d1564bf33829ba82a9d8d89da05a71d2e280d93fdfecc0"
    },
    {
        "category": "company",
        "datetime": 1738357899,
        "headline": "How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter",
        "id": 132631713,
        "image": "https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.",
        "url": "https://finnhub.io/api/news?id=2b5abdb4971c9a11192cea64ce74d24687773625f6caff8589edb139f0f00bf5"
    },
    {
        "category": "company",
        "datetime": 1738343816,
        "headline": "AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute",
        "id": 132631714,
        "image": "https://s.yimg.com/ny/api/res/1.2/RPPJBnd.GjIkjnTLlYYJ0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/21b4fc00-dff7-11ef-bf3d-13a482249c9b",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue guidance for new drugs Skyrizi and Rinvoq. Vertex Pharmaceuticals (VRTX) stock is rising after receiving approval by the Food and Drug Administration (FDA) over its new non-opioid pain management drug, Journavx. Lastly, oil giants Exxon Mobil (XOM) and Chevron (CVX) move lower as the industry is monitoring the long-term impacts of President Trump's tariffs. Stay up to date on the latest market action, minute-by-minute, with\u00a0Yahoo Finance's Market Minute. This post was written by Luke Carberry Mogan.",
        "url": "https://finnhub.io/api/news?id=684bc6bb1933c00be14cde32b294316d46713d92779f31132e9cd989f88f3c84"
    },
    {
        "category": "company",
        "datetime": 1738331419,
        "headline": "Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug",
        "id": 132506039,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.",
        "url": "https://finnhub.io/api/news?id=b7b6893bd26006818b68ec07a5dd796182e6a4db983de36d10c05ad7bcab128a"
    },
    {
        "category": "company",
        "datetime": 1738321020,
        "headline": "Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller",
        "id": 134149238,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller",
        "url": "https://finnhub.io/api/news?id=abc9d0c48ec48d78d5024ba1532cac0b8cb962da548d9b36ed322d4e7cec32ce"
    },
    {
        "category": "company",
        "datetime": 1738316850,
        "headline": "Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller",
        "id": 132524575,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller",
        "url": "https://finnhub.io/api/news?id=bd18e30013bd3f250817d274542ab5403914477f797be823620784c95d14d368"
    },
    {
        "category": "company",
        "datetime": 1738305252,
        "headline": "Vertex Announces FDA Approval of JOURNAVX, a First-in-Class Treatment for Adults with Moderate-to-Severe Acute Pain",
        "id": 132504014,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved JOURNAVX , an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for...",
        "url": "https://finnhub.io/api/news?id=3eb4adf72bf3dfa6294a2b8e348b71fe5c5598955b7bbb45ed7732b4313ce03d"
    },
    {
        "category": "company",
        "datetime": 1738300033,
        "headline": "FDA approves painkiller designed to eliminate the risk of addiction associated with opioids",
        "id": 132503590,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "WASHINGTON \u2014 Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin....",
        "url": "https://finnhub.io/api/news?id=a0b59e6a8271dac40d6b868498225514f9f6e5ba3c362f3bb919bc68d4f0c3d9"
    },
    {
        "category": "company",
        "datetime": 1738298100,
        "headline": "Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.",
        "id": 132524595,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.",
        "url": "https://finnhub.io/api/news?id=72bcbae22c093bd52d6efdc47f209a6218da523ab9c45966c436ec895299af26"
    },
    {
        "category": "company",
        "datetime": 1738264380,
        "headline": "Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug",
        "id": 132524576,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug",
        "url": "https://finnhub.io/api/news?id=99d0034540e0c9a38e34f12072ff73fc8e348f62ac484301677fd29d315a19a3"
    },
    {
        "category": "company",
        "datetime": 1738144260,
        "headline": "Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.",
        "id": 134149240,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.",
        "url": "https://finnhub.io/api/news?id=5848685c3b5f5e42594b640576869203301a35b36034b51836d79b5880f64acf"
    },
    {
        "category": "company",
        "datetime": 1738140600,
        "headline": "Moderna\u2019s stock is falling. Goldman Sachs says it\u2019s no longer a buy.",
        "id": 132524597,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Moderna\u2019s stock is falling. Goldman Sachs says it\u2019s no longer a buy.",
        "url": "https://finnhub.io/api/news?id=2f7192b9d7a65831e6d6af2b4e8e256915e1d48c9e15f8e405b643f59a2dd076"
    },
    {
        "category": "company",
        "datetime": 1737963063,
        "headline": "Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10",
        "id": 132478785,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "Vertex Pharmaceuticals Incorporated will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a...",
        "url": "https://finnhub.io/api/news?id=cb430cb984f982b021b1e77ab45c7da6c7209436131c8af0340a49035078e996"
    },
    {
        "category": "company",
        "datetime": 1737640920,
        "headline": "ClearBridge Growth Fund Q4 2024 Commentary",
        "id": 132449938,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Performance was supported in the quarter by AI-indexed semiconductor and software provider Broadcom, along with a cohort of disruptors. Read more here.",
        "url": "https://finnhub.io/api/news?id=e1e3344f16b9895b1257ed6e487791c25524d6f5b2ff9b0f7144ada59dfc5aa8"
    },
    {
        "category": "company",
        "datetime": 1737543300,
        "headline": "Baron Health Care Fund Q4 2024 Shareholder Letter",
        "id": 132442862,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Baron Health Care Fund retreated in the fourth quarter of 2024, in line with its benchmark, the Russell 3000 Health Care Index. Read more here.",
        "url": "https://finnhub.io/api/news?id=0271890740cb4d946feb67364f9ef0cbee944c4e8517254a2ede741d5201d864"
    },
    {
        "category": "company",
        "datetime": 1737200400,
        "headline": "3 Unstoppable Stocks to Buy in 2025",
        "id": 132421521,
        "image": "https://g.foolcdn.com/editorial/images/804255/2025-with-stock-chart.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Three Motley Fool contributors believe they've identified healthcare stocks in the latter category.  Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025.  David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher.",
        "url": "https://finnhub.io/api/news?id=4e798ba7863d818fd5d7c0d92612bc0d8940c3ca7916188f0a45814c84d85678"
    },
    {
        "category": "company",
        "datetime": 1737068422,
        "headline": "Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know",
        "id": 132421522,
        "image": "https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.",
        "url": "https://finnhub.io/api/news?id=fbbfa4555ea0daf5036efb3fefa480d4b023c95ad313dd4747a395b9ec84bd96"
    },
    {
        "category": "company",
        "datetime": 1737024540,
        "headline": "Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?",
        "id": 132421524,
        "image": "https://g.foolcdn.com/editorial/images/803921/young-woman-looking-at-laptop.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases.  Should you buy Vertex stock hand over fist before Jan. 30?  Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare disease that affects only around 109,000 patients worldwide.",
        "url": "https://finnhub.io/api/news?id=55f9e262c1982884920a22e9dff1a99d4f9c4ea47d951cf010e1f5079c107477"
    },
    {
        "category": "company",
        "datetime": 1737008700,
        "headline": "Next Century Growth Investors Q4 2024 Commentary",
        "id": 132404982,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305707642/image_1305707642.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "In the fourth quarter of 2024, equity markets were positive and large cap stocks generally outperformed small cap stocks. Read more here.",
        "url": "https://finnhub.io/api/news?id=73e8069e54636e4d13a9d94bc0d115cbdc6cab07173db678464c129ad714ba43"
    },
    {
        "category": "company",
        "datetime": 1736968834,
        "headline": "CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers",
        "id": 132402263,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/667138650/image_667138650.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic advantages. See more here.",
        "url": "https://finnhub.io/api/news?id=a458b7b0a985e00f4908707431ebb3870473dce0c8b53766225634b7777b5203"
    },
    {
        "category": "company",
        "datetime": 1736884029,
        "headline": "Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials",
        "id": 132421526,
        "image": "https://media.zenfs.com/en/Benzinga/935989c9db6593ae20b96f8ade791831",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Vertex raised its CF patient estimates",
        "url": "https://finnhub.io/api/news?id=6c2dfe9cef34eaa7bb107d6e376942dd1708f4e4135ab8b714302352868e9951"
    },
    {
        "category": "company",
        "datetime": 1736820420,
        "headline": "Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine",
        "id": 132391720,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/909908830/image_909908830.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is under investigation as a pain relief medication.",
        "url": "https://finnhub.io/api/news?id=f344bb58bcf671a67adde18f76ed7793db4f34c1170da5b08d9f9a109f115637"
    },
    {
        "category": "company",
        "datetime": 1736770598,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)",
        "id": 132388677,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.",
        "url": "https://finnhub.io/api/news?id=6f9b27be924a6e3e5eda016794f23c3ba2b6bbbb62d3d7354638e0318a2727b7"
    },
    {
        "category": "company",
        "datetime": 1736768525,
        "headline": "Vertex Pharmaceuticals Incorporated : J.P. Morgan Healthcare Conference Presentation 2025",
        "id": 132388422,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "J.P. MORGAN HEALTHCARE CONFERENCE RESHMA KEWALRAMANI, M.D. CEO AND PRESIDENT JANUARY 2025 \u00a92025...",
        "url": "https://finnhub.io/api/news?id=12c41206df9d62dd56e22bde8e362d285a2e2bef93fb8218deedd601e12c9ee4"
    },
    {
        "category": "company",
        "datetime": 1736719260,
        "headline": "Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings",
        "id": 132421527,
        "image": "https://media.zenfs.com/en/business-wire.com/975c96962d0c8cecec94e5083a3e35e9",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "BOSTON, January 12, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company\u2019s scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT.",
        "url": "https://finnhub.io/api/news?id=0e455d49e1926bbc2991c0bf7743f99a7824e01a4f2151360cd4e74eff3af0d3"
    },
    {
        "category": "company",
        "datetime": 1736599281,
        "headline": "Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement",
        "id": 132378905,
        "image": "https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex\u2019s povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore. Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL being studied for the treatment of Immunoglobulin A nephropathy and other B cell-mediated diseases. Under the terms of the agreement, Vertex will receive an upfront",
        "url": "https://finnhub.io/api/news?id=c998066efd42e2ea2450dd2d9683504eb110265f6973662f7bdf6585b7c97c8d"
    },
    {
        "category": "company",
        "datetime": 1736549422,
        "headline": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know",
        "id": 132421529,
        "image": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (VRTX) closed at $409.56 in the latest trading session, marking a -0.62% move from the prior day.",
        "url": "https://finnhub.io/api/news?id=94547d960cc9e43159643399ab73e25cc13b240f8fb5449c0e6cf38e888c7f09"
    },
    {
        "category": "company",
        "datetime": 1736527208,
        "headline": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
        "id": 132368179,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "INCY vs. VRTX: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=b9a53d8f404b379671bb489460cd241eb67493587ea62323d7d571e00f74f722"
    },
    {
        "category": "company",
        "datetime": 1736516533,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials",
        "id": 132365511,
        "image": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "ClearBridge Investments, an investment management company, released its \u201cClearBridge Growth Strategy\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid [\u2026]",
        "url": "https://finnhub.io/api/news?id=3d394a7d9e03689e05c2f8ba0ab7643702fd0451347acb42a52b5940f530c46e"
    },
    {
        "category": "company",
        "datetime": 1736512200,
        "headline": "Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore",
        "id": 132365514,
        "image": "https://media.zenfs.com/en/business-wire.com/e45bfeaed8099e1bf7234c6bbbb395fd",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "BOSTON & SHANGHAI & CAMBRIDGE, Mass., January 10, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex\u2019s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
        "url": "https://finnhub.io/api/news?id=a8e283b1a922fb3eae8d500dc5ca6e7031c5af5b13984da9216b7f2662f27a93"
    },
    {
        "category": "company",
        "datetime": 1736512200,
        "headline": "Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore",
        "id": 132365512,
        "image": "https://media.zenfs.com/en/business-wire.com/43d45085c716710adc7ef32df488f446",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "SHANGHAI & CAMBRIDGE, Mass. & BOSTON, January 10, 2025--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex\u2019s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and",
        "url": "https://finnhub.io/api/news?id=58248d5a8d38254809e61aa72ce68346cc0be48dfbaeab4f8493d416aa115bba"
    },
    {
        "category": "company",
        "datetime": 1736506824,
        "headline": "An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued",
        "id": 132365515,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Key Insights Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex...",
        "url": "https://finnhub.io/api/news?id=e1ae84aefa14a29b05cbeec4e35a198d2081e0a784329b52b5ce9b76a205e1b9"
    },
    {
        "category": "company",
        "datetime": 1736421300,
        "headline": "ClearBridge Growth Strategy Q4 2024 Commentary",
        "id": 132348792,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385299427/image_1385299427.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the fourth quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=a062d5834c0cc6d55153a6cdeb3395c34fbd59bc73b0c15d504a33195b56b2c5"
    },
    {
        "category": "company",
        "datetime": 1736338863,
        "headline": "Vertex and Orna sign partnership to improve efficiencies of gene therapies",
        "id": 132316166,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/01/GettyImages-1916729901-e1736334692695.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.",
        "url": "https://finnhub.io/api/news?id=7636f2207ae6674c6ad14bdd731d1d36d214ecd8e8b7d60050d2e084399351ba"
    },
    {
        "category": "company",
        "datetime": 1736330065,
        "headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia",
        "id": 132315965,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "WATERTOWN - Orna Therapeutics announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated to utilize Orna's novel and proprietary LNP delivery solutions to...",
        "url": "https://finnhub.io/api/news?id=c047f12ce5ad5d71f0894e6285beca7cf932a45cb7d0d0894ddd06d1b1f74f97"
    },
    {
        "category": "company",
        "datetime": 1736307720,
        "headline": "2024 Performance Review And Future Strategy",
        "id": 132312972,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about my 2024 performance here.",
        "url": "https://finnhub.io/api/news?id=3922811a6b45756cc6f38314d6b95f2b71818045c9380e9535a68114ed74797a"
    },
    {
        "category": "company",
        "datetime": 1736252391,
        "headline": "Vertex, startup Orna to partner on gene editing research",
        "id": 132304363,
        "image": "https://imgproxy.divecdn.com/C-892h3p5lr2Zt4br4ikUquWE6YXvZGAkfTDE7aaWto/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CT1NfSFFfZXh0ZXJpb3JfVmVydGV4LmpwZw==.webp",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The three-year partnership is another example of Vertex\u2019s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.",
        "url": "https://finnhub.io/api/news?id=3ed405aef7f32f8f789a02afc9fbb6143307121bbb0ae4cfc48e1362c5e20bb1"
    },
    {
        "category": "company",
        "datetime": 1736251200,
        "headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)",
        "id": 132298862,
        "image": "https://media.zenfs.com/en/prnewswire.com/304c20486dafc7039794e2602467bb6a",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to utilize Orna's novel and proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with SCD and TDT.",
        "url": "https://finnhub.io/api/news?id=ac351f928d5b7755fb03e9c8ac6118178043b8d4bd69fd9cdfd60fa4ba5556f9"
    },
    {
        "category": "company",
        "datetime": 1736249479,
        "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
        "id": 132302431,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
        "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    },
    {
        "category": "company",
        "datetime": 1736204423,
        "headline": "Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note",
        "id": 132298863,
        "image": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=79d11a83248f9ef91c8ad14cededa49ac6a41aae5809078ddba222e17923c495"
    },
    {
        "category": "company",
        "datetime": 1736157784,
        "headline": "3 US Stocks Estimated To Be Undervalued By Up To 42%",
        "id": 132288320,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "As the U.S. stock market begins to rebound from a sluggish start in 2025, with major indices like the S&P 500 and Nasdaq snapping multi-day losing streaks, investors are keenly observing opportunities that may arise from recent volatility. In this context, identifying undervalued stocks becomes crucial as they can offer potential value by trading below their intrinsic worth amidst fluctuating market conditions.",
        "url": "https://finnhub.io/api/news?id=35e5ee27f901f8152d5de48444f4806450c62e51114aa81bd43bf585546600a2"
    },
    {
        "category": "company",
        "datetime": 1735836120,
        "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
        "id": 132325439,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=da7234e2629dca5d80bf855f14c963dc9ebcfc07c05667ca3671221effa0f5b9"
    },
    {
        "category": "company",
        "datetime": 1735753402,
        "headline": "Jim Cramer\u2019s Take on Vertex Pharmaceuticals (VRTX): Bold Predictions for the Future",
        "id": 132233041,
        "image": "https://media.zenfs.com/en/insidermonkey.com/a6c6a869a7c2c92171425bdb9b9fb0f6",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the Jim Cramer\u2019s Bold Predictions About These 10 Healthcare Stocks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been one of Jim Cramer\u2019s favorite topics lately. [\u2026]",
        "url": "https://finnhub.io/api/news?id=288a4e0d00c3ef5ca5f244baa6ab7f20de4bac91732d31218b959ff0eb4cc07b"
    },
    {
        "category": "company",
        "datetime": 1735740012,
        "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
        "id": 132228881,
        "image": "https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "url": "https://finnhub.io/api/news?id=ca12359f885e4afa5f3ea497eb71e8e82e254178dcc43670e9a73d26e0d03611"
    },
    {
        "category": "company",
        "datetime": 1735642834,
        "headline": "Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%",
        "id": 132215226,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price drop...",
        "url": "https://finnhub.io/api/news?id=5f5e0bd3db8ccc21039bbea2bdcc77858ac2dcce68136aae64db88aacda8077a"
    },
    {
        "category": "company",
        "datetime": 1735635767,
        "headline": "Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested",
        "id": 132214140,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291337814/image_1291337814.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified pipeline. See my thoughts on VRTX.",
        "url": "https://finnhub.io/api/news?id=7756a79ae04b7af7be36a314afde90b18c95f235f326ab60e48b363f7e3fab96"
    },
    {
        "category": "company",
        "datetime": 1735565400,
        "headline": "Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?",
        "id": 132205249,
        "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.",
        "url": "https://finnhub.io/api/news?id=cde8639c69f474a6cbb02079e6794e15ebc6f17f826293ea72b52de8b9ab1917"
    },
    {
        "category": "company",
        "datetime": 1735476961,
        "headline": "Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025",
        "id": 132195988,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1992633051/image_1992633051.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects.",
        "url": "https://finnhub.io/api/news?id=72c4541b7da7363fd94818cdec79a4380c55699157ee15a82fb1b28506d7dcfb"
    },
    {
        "category": "company",
        "datetime": 1735390800,
        "headline": "Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip",
        "id": 132186378,
        "image": "https://g.foolcdn.com/editorial/images/801957/physician-giving-medicine-to-elderly-patient.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment.  Its first approved indication could come as early as next month in treating acute pain.  It will seek label expansions thereafter, including in targeting painful lumbosacral radiculopathy (LSR, a condition that results from a pinched or inflamed nerve in the lower back).",
        "url": "https://finnhub.io/api/news?id=397d55ec2401b6070b8dc58d0893551351b1f2b0640a5ef821341d9e313528bf"
    },
    {
        "category": "company",
        "datetime": 1735224180,
        "headline": "The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics",
        "id": 132164919,
        "image": "https://media.zenfs.com/en/zacks.com/03f63cde809dc0b9100c223e177450af",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=22180e22df7c14ec33162ab891f96bea3a0e7a178cd9767eb9209acc9bd93aa5"
    },
    {
        "category": "company",
        "datetime": 1735219800,
        "headline": "Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip",
        "id": 132165191,
        "image": "https://g.foolcdn.com/editorial/images/801997/two-investors-consider-a-stock-with-laptop.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial.  Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF).  Its steady work over the year delivered a large market share in CF therapies.",
        "url": "https://finnhub.io/api/news?id=bc6828dbe71cce234e47eb4bf8fac802a80553fafb8874593f0a6bc4360b1ff0"
    },
    {
        "category": "company",
        "datetime": 1735131109,
        "headline": "Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): \u2018This Is Hardly Down For The Year. I Think It Can Still Go Lower\u2019",
        "id": 132165192,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed\u2019s interest rate cut, Jim Cramer had [\u2026]",
        "url": "https://finnhub.io/api/news?id=372f2a0f86d310623148f538600bc4a580c12fb2b5b0f381853fa02ab1e843fa"
    },
    {
        "category": "company",
        "datetime": 1735126214,
        "headline": "Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst",
        "id": 132142968,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. \"This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo,\" BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. \"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit,\" he goes on to say to Brad Smith and Josh Lipton. Seigerman \u2014 who maintains an Outperform rating Novo Nordisk \u2014 also comments on the impact the incoming Trump administration could have on the pharma space, particularly with Robert F. Kennedy Jr. assuming the role of secretary of the Department of Health and Human Services (HHS): \"I think the first thing he could do would be make it more challenging for Medicare to cover GLP-1s for things like heart disease and sleep apnea. That's a big hypothetical...\" To watch more expert insights and analysis on the latest market action, check out more Market Domination\u00a0here. This post was written by Luke Carberry Mogan.",
        "url": "https://finnhub.io/api/news?id=dc451877af6528648c9f98a400db1211a380257b2ab5b236d5154b20ce503913"
    },
    {
        "category": "company",
        "datetime": 1735099352,
        "headline": "Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?",
        "id": 132140561,
        "image": "https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks that will make you rich in 2025. What to Expect from the Stock Market in 2025 Jurrien Timmer, Director [\u2026]",
        "url": "https://finnhub.io/api/news?id=464eeda34434e7a8850f3fdc91fc00818fe501a9c29adfb2712179cdafbc4a94"
    },
    {
        "category": "company",
        "datetime": 1735080619,
        "headline": "Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know",
        "id": 132140562,
        "image": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.",
        "url": "https://finnhub.io/api/news?id=a5e21f564e52caed4a2fffab589c30f6e9c7999ba5a48e54a5d2888ff2f21615"
    },
    {
        "category": "company",
        "datetime": 1735069320,
        "headline": "Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals",
        "id": 132136766,
        "image": "https://media.zenfs.com/en/zacks.com/234b27bba87616a250ccab2b188f127a",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corporation (TM) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks BK Technologies Corporation (BKTI) and Servotronics, Inc. (SVT).",
        "url": "https://finnhub.io/api/news?id=6d26057dc5b9439eb8123a50f4a0c738667580e1ef7139f38f0ce43637fcf5a6"
    },
    {
        "category": "company",
        "datetime": 1735058520,
        "headline": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
        "id": 132148889,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=51197698ba61a8094b1c6d7f875e1f0b4caf463b6c1edbd4b52e1177af56e909"
    },
    {
        "category": "company",
        "datetime": 1735051832,
        "headline": "Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist",
        "id": 132131918,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Truist analyst Joon Lee lowered the firm\u2019s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy rating on the shares. The firm moderates its view of the odds of success of suzetrigine in chronic pain to 30% from 60% after \u201cdisappointing\u201d Phase 2 results in lumbosacral radiculopathy. The early approval of vanza triple, or Alyftrek, is \u201cpositive, but was largely expected,\u201d adds the analyst, who sees upside from pipeline updates in 2025. Published first on TheFly \u2013 the ul",
        "url": "https://finnhub.io/api/news?id=54a0ce77807228f886171394568ae959bb87e30b82e66118e2f342c22c05db82"
    },
    {
        "category": "company",
        "datetime": 1735035900,
        "headline": "3 No-Brainer Stocks to Buy on the Latest Sell-Off",
        "id": 132129785,
        "image": "https://g.foolcdn.com/editorial/images/801947/stock-chart-falling-with-man-holding-hand-to-head.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Warren Buffett's mentor Benjamin Graham once said, \"In the short run, the market is a voting machine but in the long run, it is a weighing machine.\"  Graham also knew, though, that business fundamentals matter over the long term.  In fact, the temporary pullbacks make them even better choices because the stocks are available at more attractive prices.",
        "url": "https://finnhub.io/api/news?id=b50ae7e79bf00d9355c1609c402bc4911a2db6088a595e46a5efcc3d4f470799"
    },
    {
        "category": "company",
        "datetime": 1735028344,
        "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): \u2018Their Painkiller Equaled The Placebo. And That\u2019s Just A Shame\u2019",
        "id": 132129312,
        "image": "https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed\u2019s Rate Cut. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve created quite a bit of turmoil in the [\u2026]",
        "url": "https://finnhub.io/api/news?id=41f2635e773a057af45f94d8dec9ed4e1557b5167975fda338caacf24e059fd9"
    },
    {
        "category": "company",
        "datetime": 1734979440,
        "headline": "Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek",
        "id": 132123050,
        "image": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.",
        "url": "https://finnhub.io/api/news?id=0287a80b570ce2e587c5c8ff0c162fb1c89dba5ab454a2cfc3010a83d0809725"
    },
    {
        "category": "company",
        "datetime": 1734969963,
        "headline": "Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13",
        "id": 132122951,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "Vertex Pharmaceuticals Incorporated today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...",
        "url": "https://finnhub.io/api/news?id=18a4be297cf888d7df014a999409c6612a89f6ae585bcd12c153b0b110499807"
    },
    {
        "category": "company",
        "datetime": 1734957556,
        "headline": "Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings",
        "id": 132118176,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2375295861-e1734953365392.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.",
        "url": "https://finnhub.io/api/news?id=0c59904bab750294a6b6a33839bbfd40ed9f80e17c37a28415f8ed16d952bb12"
    },
    {
        "category": "company",
        "datetime": 1734953199,
        "headline": "Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
        "id": 132120314,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis...",
        "url": "https://finnhub.io/api/news?id=0cc1317eadcb1504d9209b008edccae8b5ff5652f119c9af39c4f40fb1cfba05"
    },
    {
        "category": "company",
        "datetime": 1734953198,
        "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
        "id": 132120317,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration has approved the expanded use of TRIKAFTA for the treatment of people with cystic fibrosis ages 2...",
        "url": "https://finnhub.io/api/news?id=bea9620375072e454a58735183c5f31dcbbf82d6d2361021bbb41ec79f110357"
    },
    {
        "category": "company",
        "datetime": 1734930900,
        "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
        "id": 132116815,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827"
    },
    {
        "category": "company",
        "datetime": 1734888300,
        "headline": "This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?",
        "id": 132112267,
        "image": "https://g.foolcdn.com/editorial/images/800098/physician-giving-a-high-five-to-a-young-patient.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions.  This new coverage could also make it easier once CRISPR Therapeutics earns approval for other gene-editing medicines.",
        "url": "https://finnhub.io/api/news?id=a1c5818b50b560ef8a8831517730c6a5d6c5136684913c6ee10214e50685a655"
    },
    {
        "category": "company",
        "datetime": 1734859800,
        "headline": "Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?",
        "id": 132107420,
        "image": "https://g.foolcdn.com/editorial/images/801725/gettyimages-research-team-smiles-in-lab.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November.  The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.  Meanwhile, Vertex is heading for two pieces of news in January that could be enormous for the company.",
        "url": "https://finnhub.io/api/news?id=9cf02dbce7fd15aa07371d1ed2ae24b7247ab84c9cf459d146c022f7614b6cd5"
    },
    {
        "category": "company",
        "datetime": 1734784225,
        "headline": "Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein",
        "id": 132098059,
        "image": "https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Bernstein lowered the firm\u2019s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform rating on the shares. The firm thinks suzetrigine is at least somewhat active in diabetic peripheral neuropathy based on the prior small fiber neuropathy trial of VX-150, but probably no better than what has been seen in recent Lyrica trials, and those trials have shown fairly modest delta vs. placebo, the analyst tells investors in a research note. If the firm can\u2019t get reason",
        "url": "https://finnhub.io/api/news?id=41b899b508fcadf3e70a9646d82e3148b7c75d3a9630c9264f1d3587b1b1e44f"
    },
    {
        "category": "company",
        "datetime": 1734781680,
        "headline": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
        "id": 132093791,
        "image": "https://g.foolcdn.com/editorial/images/801623/santa-claus-buggy-chart.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Santa Claus will soon be on his way delivering presents to kids around the world.  Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally.  Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
        "url": "https://finnhub.io/api/news?id=c85edc7e6a3998a41c0e4e7c088a85b37e7ed01fa13441b5717ab51bff545cff"
    },
    {
        "category": "company",
        "datetime": 1734771900,
        "headline": "My Top 10 Stocks to Buy for 2025",
        "id": 132090473,
        "image": "https://g.foolcdn.com/editorial/images/801386/gettyimages-1070239362.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Most of these stocks have a solid earnings track record (except for the clinical-stage biotech that doesn't yet generate product revenue).  A key catalyst is unfolding right now: This top artificial intelligence (AI) chip designer is ramping production of its Blackwell architecture, and demand is \"staggering,\" the company has said.  Nvidia's commitment to innovation should keep it ahead of rivals, making the stock looked reasonably priced today at 43x forward earnings estimates.",
        "url": "https://finnhub.io/api/news?id=a8d105624d7dc9b8a3e61a846be3a8c127bb3234d0da9023e8414c9b5e6873e6"
    },
    {
        "category": "company",
        "datetime": 1734762785,
        "headline": "What Moved Markets This Week",
        "id": 132093213,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356756815/image_1356756815.jpg?io=getty-c-w1536",
        "related": "VRTX",
        "source": "SeekingAlpha",
        "summary": "Wall Street suffered its worst weekly loss in over a month on Friday on Fed comments after another rate cut. Read more about this week's major events on Wall Street.",
        "url": "https://finnhub.io/api/news?id=3da869743e802bd8b73bcabd51e34f28d0e7cf941df870dbfc46ac6443ec1f95"
    },
    {
        "category": "company",
        "datetime": 1734736567,
        "headline": "Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock",
        "id": 132084060,
        "image": "https://media.zenfs.com/en/ibd.com/df5c1a56168deebdebe2aceaa3ac053c",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.",
        "url": "https://finnhub.io/api/news?id=a6d538f800498a68bf7629a63d2ab6eec1c8fd7231a9e240c823f311f7a2e495"
    },
    {
        "category": "company",
        "datetime": 1734727560,
        "headline": "Vertex Announces US FDA Approval of ALYFTREK\u2122, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
        "id": 132084061,
        "image": "https://media.zenfs.com/en/business-wire.com/8f983a5f283acdb0d5d561ae2bf5f727",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Se",
        "url": "https://finnhub.io/api/news?id=931ce3e47b31a4c4dfd483cb6576ea152afd39ee4a029a455962c6b74b50d6e3"
    },
    {
        "category": "company",
        "datetime": 1734726900,
        "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
        "id": 132084062,
        "image": "https://media.zenfs.com/en/business-wire.com/1d6c5d7e0aecf1598be4064357d8307a",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In a",
        "url": "https://finnhub.io/api/news?id=a50107a1907b446af20a4885fa4010096f4c7cc189f613e352145452b6521bc8"
    },
    {
        "category": "company",
        "datetime": 1734711920,
        "headline": "Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek",
        "id": 132079754,
        "image": "",
        "related": "VRTX",
        "source": "Finnhub",
        "summary": "By Katherine Hamilton Vertex Pharmaceuticals said the Food and Drug Administration approved a new treatment for cystic fibrosis. The treatment, called alyftrek, is designed to treat cystic...",
        "url": "https://finnhub.io/api/news?id=76e4ff17a5ba435f66bfb9579381332737c67279dace4ed6b1944294eabd6885"
    },
    {
        "category": "company",
        "datetime": 1734711180,
        "headline": "VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo",
        "id": 132084064,
        "image": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.",
        "url": "https://finnhub.io/api/news?id=71f00e9a21497f7d70f4aa6f9a7b22eb919237ab28e477aed080c471bd62792a"
    },
    {
        "category": "company",
        "datetime": 1734710400,
        "headline": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
        "id": 132148892,
        "image": "",
        "related": "VRTX",
        "source": "MarketWatch",
        "summary": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
        "url": "https://finnhub.io/api/news?id=3f786a6b0462b7b8cbe2e93e70ac9ce83e28ddfdb49f4b56d0d95e42b9dbc7f3"
    },
    {
        "category": "company",
        "datetime": 1734699615,
        "headline": "Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?",
        "id": 132084065,
        "image": "https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.",
        "url": "https://finnhub.io/api/news?id=4256c0fd3307dadb6e0e04005880f6000e548f25473fcf41339213d94f2143f0"
    },
    {
        "category": "company",
        "datetime": 1734697221,
        "headline": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
        "id": 132148870,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
        "url": "https://finnhub.io/api/news?id=7d942acb9b559d2d1c72580d2cfc3eb55df24134a9cd3e7782717958add180b9"
    },
    {
        "category": "company",
        "datetime": 1734644658,
        "headline": "S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat",
        "id": 132059998,
        "image": "https://www.investopedia.com/thmb/gKQgfpi97bBTaUaR5dfhEpcYGv0=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2155206502-5a8269261f8e477fb14ff4b861a0c5ab.jpg",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's sell-off despite upbeat data on economic growth.",
        "url": "https://finnhub.io/api/news?id=e85e292d5fc4aacadcac987aa9771ff3e40cf4bae9bc84ab5281b12028ff5502"
    },
    {
        "category": "company",
        "datetime": 1734643174,
        "headline": "Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
        "id": 132061462,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
        "url": "https://finnhub.io/api/news?id=28537cacbff90acc7997934f9cc22fbf4ee418f0d7155fa5427c26116737906e"
    },
    {
        "category": "company",
        "datetime": 1734642319,
        "headline": "Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): \u2018I Think You Should Buy The Dip Here\u2019",
        "id": 132061463,
        "image": "https://s.yimg.com/ny/api/res/1.2/IL7L4DNCC04XechOcC.G2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently reflected on how investors often overlook obvious [\u2026]",
        "url": "https://finnhub.io/api/news?id=eed13949b150389a2183134b36c753e4b46ff216ef7549795f9e19752540d1a1"
    },
    {
        "category": "company",
        "datetime": 1734631592,
        "headline": "Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?",
        "id": 132055336,
        "image": "https://media.zenfs.com/en/Benzinga/66f98a38463887e6a39061b6ed232033",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically significant and clinically mean",
        "url": "https://finnhub.io/api/news?id=af95b2e315ebeabd386513625fb4d6e445db6e9d127389ee7b9ac56de510df6e"
    },
    {
        "category": "company",
        "datetime": 1734630394,
        "headline": "Vertex Dives 13% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug",
        "id": 132055338,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.",
        "url": "https://finnhub.io/api/news?id=fdd940e4092cd7ddb159930e1418d4aec16ef704cb2f4fabbe85d1a97a2fee20"
    },
    {
        "category": "company",
        "datetime": 1734627702,
        "headline": "Accenture, Robinhood and Coinbase, Vertex: Market Minute",
        "id": 132054347,
        "image": "https://s.yimg.com/ny/api/res/1.2/A1IJhRrCRNfCTTYuzKRuIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/ddc95d80-be2a-11ef-9dff-1bd76624dea6",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "Yahoo Finance host Rachelle Akuffo dives into three stories from several of the top trending stock tickers on the Yahoo Finance platform. Accenture (ACN) shares are popping after topping its fiscal first quarter earnings estimates. Brokerage site Robinhood Markets (HOOD) and crypto exchange Coinbase Global (COIN) see their stocks move higher amid bitcoin's recent volatility (BTC-USD). Lastly, Vertex Pharmaceuticals (VRTX) shares are dropping Thursday morning in response to its Phase 2 trial results for its new non-opioid painkiller. To watch more expert insights and analysis on the latest market action, check out more Wealth\u00a0here. This post was written by Luke Carberry Mogan.",
        "url": "https://finnhub.io/api/news?id=147e45ae4b161e4c6b4e511f8aae60faa590af9f5e338b4e87b79541bb41ade9"
    },
    {
        "category": "company",
        "datetime": 1734625008,
        "headline": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
        "id": 132063917,
        "image": "",
        "related": "VRTX",
        "source": "DowJones",
        "summary": "Stock Market Today: Dow Jones Looks To End Losing Streak; AI Name Ends Long Win Streak (Live Coverage)",
        "url": "https://finnhub.io/api/news?id=f159582f43343fe22cee891d5aa737f9ad960c7090022b84b39c4c98966ed842"
    },
    {
        "category": "company",
        "datetime": 1734622980,
        "headline": "Vertex Pain Drug Doesn\u2019t Beat Placebo. The Company Says It Still Sees Promise.",
        "id": 132055340,
        "image": "",
        "related": "VRTX",
        "source": "Yahoo",
        "summary": "The company\u2019s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.",
        "url": "https://finnhub.io/api/news?id=0bd70feff850e1befa4461e40c750950ce6f1f50e3fa567c039adacf719d8e9d"
    }
]